Literature DB >> 33141259

Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis.

Chan Park1, Dong Il Gwon2, Hee Ho Chu1, Jong Woo Kim1, Jin Hyoung Kim1, Gi-Young Ko1.   

Abstract

PURPOSE: To evaluate associations between pathology and CT assessments made according to the mRECIST in HCC treated by conventional TACE (cTACE), and to identify predictors of complete tumor necrosis.
METHODS: From March 2016 to July 2018, 83 patients with a total of 100 masses were retrospectively included. Patients underwent sequential cTACE and portal vein embolization, and later hepatic surgery. Evaluation of treatment response and measurement of baseline lipiodol accumulation as mean HU was performed on CT at the time point closest to the time of operation (mean, 54.5 days after cTACE). Significant predictors associated with complete necrosis were identified by multivariate analysis. The optimal cut-off HU value of lipiodol accumulation for prediction of complete necrosis was determined using a ROC analysis.
RESULTS: According to mRECIST, complete response (CR, n = 70) and partial response (n = 30) were classified. 34.3% (24/70) masses classified as CR according to mRECIST were found to have viable lesions on pathology. On multivariate analysis, mean HU of lipiodol accumulation was the only significant predictor of complete necrosis (p = .003, odds ratio 1.746, 95% CI 1.201-2.539). On ROC analysis, 460 HU as a cut-off value was significantly associated with complete necrosis (67.4% sensitivity, 75.0% specificity).
CONCLUSIONS: A threshold value for lipiodol accumulation > 460 HU was highly sensitive and specific for complete necrosis, even in complete response according to mRECIST. Therefore, if lipiodol accumulation is insufficient in post-TACE CT, recurrence should be monitored more sensitively.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hepatocellular carcinoma; Lipiodol; Necrosis; Response assessment; TACE; mRECIST

Mesh:

Substances:

Year:  2020        PMID: 33141259     DOI: 10.1007/s00261-020-02845-4

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  21 in total

Review 1.  Loco-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 2.  Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.

Authors:  Vahid Yaghmai; Cecilia Besa; Edward Kim; Joseph L Gatlin; Nasir A Siddiqui; Bachir Taouli
Journal:  AJR Am J Roentgenol       Date:  2013-07       Impact factor: 3.959

3.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Chung-Mau Lo; Henry Ngan; Wai-Kuen Tso; Chi-Leung Liu; Chi-Ming Lam; Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

4.  Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.

Authors:  K Takayasu; S Arii; N Matsuo; M Yoshikawa; M Ryu; K Takasaki; M Sato; N Yamanaka; Y Shimamura; M Ohto
Journal:  AJR Am J Roentgenol       Date:  2000-09       Impact factor: 3.959

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 6.  Chemoembolization of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Pasquale Petruzzi; Laura Crocetti
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

7.  Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective.

Authors:  Kenichi Takayasu
Journal:  Oncology       Date:  2013-02-20       Impact factor: 2.935

8.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?

Authors:  Nathan Haywood; Kyle Gennaro; John Obert; Paul F Sauer; David T Redden; Jessica Zarzour; J Kevin Smith; David Bolus; Souheil Saddekni; Ahmed Kamel Abdel Aal; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay
Journal:  J Oncol       Date:  2016-02-02       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.